ANZCTR search results

Current evidence on optimal pain management in the ED is limited, with opioids often prescribed without robust data on safety and effectiveness. Some studies have suggested that opioids, like oxycodone, can increase the risk of adverse events, and potential risks of misuse and dependency. There is a need to establish whether non-opioid analgesics can provide effective pain relief. ADAPT-ED addresses these gaps by testing multiple analgesic strategies within a single trial framework and adopting an adaptive design that enables efficient identification of effective treatments and early discontinuation of ineffective ones.

Kidney injury is common after lung transplantation surgery. Most commonly a drug called noradrenaline is used to maintain blood pressure around the time of the operation. Other research has suggested a new drug called angiotensin II may be of benefit. In this study we aim to carry out research to determine whether a large study of angiotensin II in lung transplantation is feasible.

The researchers will see people with CH, or who may have CH. For people who may have CH, the researchers will organise testing to confirm the condition after providing counselling. People with CH who agree to participate in the study will also have monitoring of their CH, assessment of the risk of heart diseases, and personalised support. The researchers will also measure people’s understanding of CH and how they feel after learning about CH. Researchers will then record the relevant information from people with CH in a central database over time to track long-term outcomes. The information collected from the study will help create a blueprint for doctors to provide care for people with CH in the future, and guide further research into CH.

Cellulitis is a common bacterial infection of the skin and underlying tissue. Acutely, it causes pain and swelling that significantly hinder daily activities. Longer-term, persistent oedema predisposes patients to recurrent cellulitis, creating a relentless cycle of swelling and infection. Our trial will evaluate whether adding compression therapy to standard antibiotic care at the onset of acute cellulitis can hasten can hasten resolution, avoid complications, minimise antibiotic use, and prevent recurrence. An initial internal pilot will refine procedures and support trial expansion. Our vision is to transform cellulitis management by targeting infection and oedema together, enabling faster recovery, reducing long-term disability, saving healthcare resources, and promoting antibiotic stewardship.

This is a phase 2a trial of SAT-3247 in ambulatory DMD patients aged from 7 and less than 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy. Enrollment of up to 51 ambulatory DMD participants aged from 7 and less than 10 years of age is planned. Randomization will be stratified by baseline corticosteroid regimen and prior DMD concomitant medications. Each participant will receive once daily doses of SAT-3247 or matched placebo for 12 weeks. Participants will be screened within 28 days before initiating dosing of investigational product at Baseline. Following the Screening period, participants will complete a Baseline visit (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4), and Week 12 (Visit 5) follow-up visits.

CFS/ME is a debilitating disease characterised by severe, unexplained fatigue lasting for more than 6 months with additional symptoms affecting the entire body. CFS/ME has no known causes, no definitive diagnostic biomarkers, and very limited treatment options. Dysfunction of the immune system is common in CFS/ME and while many people with CFS/ME find that dietary modification can improve symptoms, the research behind this is lacking. This study therefore aims to determine whether diet and immune function differ between CFS/ME patients compared to healthy controls, and whether they possibly interact to affect symptoms of CFS/ME.

This study explores whether a single 30mg dose of Psilocybin - when given as part of Psychedelic-Assisted Therapy - can assist people who are living with Opioid Use Disorder reduce their use of non-prescribed opioids. The study will also use functional Magnetic Resonance Imaging (fMRI) to observe any changes in participants’ brain, thinking and mood.

This study will evaluate whether a structured hand hygiene program in preschools can reduce respiratory and gastrointestinal infections in children. Preschools will adopt the program in a stepped-wedge sequence over 12 months. The intervention includes teacher training, visual prompts, and routine-based handwashing practices. We hypothesise that structured hand hygiene will reduce infection incidence and illness-related absenteeism.

The purpose of this study is to find out if BEL536is safe and tolerable in healthy adults. BEL536 is a synthetic protein called a bispecific antibody which can recognise and block pathways to help reduce inflammatory responses in the body. Bispecific means that BEL536 can attach to two different targets at the same time. This is the first time BEL536 has been tested in humans and aims to assess the effects of BEL536 on healthy volunteers. 

Resair 3 is a phase 3 pragmatic multicentre, consent waiver, cluster randomised cross-over study of 51 hospitals in 9 countries that will recruit 481,774 term or near term infants (gestation >35 weeks) within 12 months to initial respiratory support with either air (21% O2) or pure (100% O2). O2 concentrations will be titrated according to preductal O2 saturations (SpO2) of healthy, full-term infants (1). The primary outcome is the need for advanced resuscitation interventions (one or more of the following: 1. Endotracheal intubation/supraglottic airway 2. Cardiac compressions 3. Adrenaline) and death before hospital discharge. Resair 3 will use interventions and data collection methods that are part of routine care. The hypothesis is that initiating resuscitation of term/near term infants with 100% oxygen and then titrating according to clinical condition and oxygen saturations will lead to reduction in the need for advanced resuscitation interventions and death before hospital discharge, compared to initiating resuscitation with 21% oxygen and then titrating upwards.